Puma Biotechnology, Inc.
Index- P/E- EPS (ttm)-1.20 Insider Own15.00% Shs Outstand42.21M Perf Week-1.55%
Market Cap85.47M Forward P/E- EPS next Y-0.08 Insider Trans-1.12% Shs Float38.63M Perf Month-27.92%
Income-49.00M PEG- EPS next Q-0.01 Inst Own68.40% Short Float8.62% Perf Quarter-13.18%
Sales200.70M P/S0.43 EPS this Y52.70% Inst Trans-0.21% Short Ratio7.37 Perf Half Y-39.94%
Book/sh0.17 P/B11.24 EPS next Y175.00% ROA-21.40% Target Price6.40 Perf Year-81.44%
Cash/sh1.65 P/C1.16 EPS next 5Y- ROE-842.40% 52W Range1.60 - 11.95 Perf YTD-37.17%
Dividend- P/FCF- EPS past 5Y38.70% ROI-17.70% 52W High-84.02% Beta1.07
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin77.60% 52W Low19.37% ATR0.18
Employees196 Current Ratio1.60 Sales Q/Q-53.50% Oper. Margin-18.50% RSI (14)40.35 Volatility7.71% 9.88%
OptionableYes Debt/Eq0.00 EPS Q/Q-120.00% Profit Margin-24.40% Rel Volume0.57 Prev Close1.84
ShortableYes LT Debt/Eq13.72 EarningsMay 05 AMC Payout- Avg Volume451.69K Price1.91
Recom2.80 SMA20-6.95% SMA50-25.88% SMA200-51.85% Volume258,529 Change3.80%
Sep-28-21Upgrade Citigroup Neutral → Buy $11
Jun-25-20Resumed BofA/Merrill Underperform $9
Oct-08-19Downgrade Goldman Neutral → Sell $24 → $8
May-10-19Downgrade Citigroup Buy → Neutral $24
May-10-19Downgrade Cantor Fitzgerald Overweight → Neutral $57 → $20
Jan-17-19Initiated Leerink Partners Mkt Perform $21
Jan-03-19Downgrade Guggenheim Buy → Neutral
Nov-19-18Upgrade Goldman Sell → Neutral
Nov-02-18Downgrade JP Morgan Neutral → Underweight
Nov-02-18Downgrade BofA/Merrill Buy → Underperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $75
Sep-17-18Initiated Goldman Sell $42
May-11-18Reiterated Stifel Buy $95 → $87
Nov-10-17Reiterated RBC Capital Mkts Sector Perform $92 → $108
Nov-10-17Reiterated Citigroup Buy $156 → $164
Oct-02-17Reiterated Stifel Buy $110 → $130
Sep-11-17Reiterated Credit Suisse Outperform $118 → $136
Jul-10-17Resumed Leerink Partners Outperform $115
Jun-06-17Reiterated RBC Capital Mkts Sector Perform $60 → $88
May-25-17Reiterated RBC Capital Mkts Sector Perform $40 → $60
May-11-22 05:31PM  
May-06-22 11:01AM  
May-05-22 06:05PM  
May-04-22 05:35PM  
Apr-28-22 03:02PM  
Apr-27-22 04:15PM  
Apr-21-22 04:11PM  
Apr-05-22 05:15PM  
Mar-10-22 08:30AM  
Mar-07-22 09:00AM  
Mar-05-22 06:13AM  
Mar-04-22 05:00PM  
Mar-03-22 06:05PM  
Feb-17-22 03:02PM  
Feb-16-22 04:15PM  
Feb-03-22 05:15PM  
Jan-20-22 05:05PM  
Jan-12-22 04:10PM  
Jan-10-22 09:38AM  
Jan-04-22 04:14PM  
Dec-10-21 12:05PM  
Dec-03-21 05:03PM  
Nov-23-21 04:07PM  
Nov-22-21 06:48AM  
Nov-20-21 11:40AM  
Nov-19-21 09:05AM  
Nov-18-21 09:55AM  
Nov-05-21 10:31AM  
Nov-04-21 06:45PM  
Oct-28-21 03:05PM  
Oct-06-21 05:01PM  
Sep-21-21 04:10PM  
Sep-07-21 05:30PM  
Aug-06-21 04:50PM  
Aug-05-21 08:25PM  
Jul-30-21 10:36AM  
Jul-29-21 03:05PM  
Jul-26-21 08:33AM  
Jul-22-21 04:15PM  
Jul-06-21 08:00AM  
Jul-02-21 05:15PM  
Jul-01-21 08:35AM  
Jun-25-21 04:33AM  
Jun-19-21 03:30AM  
Jun-04-21 05:30PM  
May-19-21 05:05PM  
May-07-21 08:52AM  
May-06-21 07:05PM  
May-04-21 05:00PM  
Apr-29-21 05:03PM  
Apr-26-21 09:04AM  
Apr-22-21 04:15PM  
Apr-13-21 05:05PM  
Mar-27-21 11:31AM  
Mar-09-21 05:26AM  
Mar-08-21 05:15PM  
Mar-05-21 01:15AM  
Mar-04-21 04:15PM  
Mar-02-21 04:20PM  
Feb-26-21 10:10AM  
Feb-25-21 04:07PM  
Feb-11-21 04:15PM  
Feb-09-21 04:15PM  
Jan-29-21 08:00AM  
Jan-26-21 04:25AM  
Jan-19-21 09:00AM  
Jan-15-21 08:03AM  
Jan-05-21 04:15PM  
Jan-04-21 04:15PM  
Dec-16-20 05:22PM  
Dec-11-20 05:00PM  
Dec-09-20 07:31PM  
Dec-05-20 11:32AM  
Dec-02-20 08:30AM  
Nov-17-20 04:15PM  
Nov-09-20 12:11PM  
Nov-06-20 04:30PM  
Nov-05-20 05:35PM  
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HUNT DOUGLAS MSee RemarksMay 03Sale2.314381,01281,900May 05 05:36 PM
NOUGUES MAXIMO FChief Financial OfficerMay 03Sale2.34165386121,228May 04 06:46 PM
NOUGUES MAXIMO FChief Financial OfficerMay 03Sale2.34165386121,228May 04 06:44 PM
NOUGUES MAXIMO FChief Financial OfficerMay 03Sale2.34165386121,228May 04 06:43 PM
AUERBACH ALAN HPresident and CEOMay 03Sale2.321,2632,9306,345,292May 04 06:37 PM
HUNT DOUGLAS MSee RemarksApr 04Sale3.084131,27182,338Apr 05 04:55 PM
NOUGUES MAXIMO FChief Financial OfficerApr 04Sale3.08206634121,393Apr 05 04:52 PM
AUERBACH ALAN HPresident and CEOApr 04Sale3.081,1983,6876,346,555Apr 05 05:41 PM
MILLER MICHAEL PATRICKDirectorMar 16Sale2.8025,65371,79252,858Mar 17 04:33 PM
NOUGUES MAXIMO FChief Financial OfficerMar 02Sale2.2616938259,423Mar 04 05:14 PM
HUNT DOUGLAS MSee RemarksMar 02Sale2.264461,00960,104Mar 04 05:11 PM
AUERBACH ALAN HPresident and CEOMar 02Sale2.261,2942,9194,386,815Mar 04 05:07 PM
HUNT DOUGLAS MSee RemarksFeb 02Sale2.475331,31760,550Feb 03 07:38 PM
NOUGUES MAXIMO FChief Financial OfficerFeb 02Sale2.4819949459,592Feb 03 05:34 PM
AUERBACH ALAN HPresident and CEOFeb 02Sale2.461,3163,2394,388,109Feb 03 05:29 PM
AUERBACH ALAN HPresident and CEOJan 03Sale3.1922,87572,9234,389,425Jan 05 05:12 PM
NOUGUES MAXIMO FChief Financial OfficerJan 03Sale3.197,48423,87159,791Jan 05 05:04 PM
Ludwig Jeffrey JeromeChief Commercial OfficerJan 03Sale3.204,72715,12131,342Jan 05 08:32 PM
HUNT DOUGLAS MSee RemarksJan 03Sale3.213,70711,89061,083Jan 05 06:03 PM
Wong Alvin FChief Scientific OfficerDec 02Sale2.911,1313,29417,152Dec 06 06:55 PM
HUNT DOUGLAS MSee RemarksDec 02Sale2.904411,27964,790Dec 06 08:33 PM
NOUGUES MAXIMO FChief Financial OfficerDec 02Sale2.9516247867,275Dec 06 06:37 PM
AUERBACH ALAN HPresident and CEODec 02Sale2.901,8375,3274,412,300Dec 06 06:31 PM
NOUGUES MAXIMO FChief Financial OfficerNov 02Sale5.6715688567,437Nov 03 06:22 PM
HUNT DOUGLAS MSee RemarksNov 02Sale5.644272,40965,231Nov 03 06:20 PM
AUERBACH ALAN HPRESIDENT AND CEONov 02Sale5.631,79510,1124,414,137Nov 03 06:17 PM
NOUGUES MAXIMO FChief Financial OfficerOct 04Sale6.2016199867,593Oct 06 05:20 PM
HUNT DOUGLAS MSee RemarksOct 04Sale6.154432,72665,658Oct 06 05:15 PM
AUERBACH ALAN HPresident and CEOOct 04Sale6.151,85811,4334,415,932Oct 06 05:04 PM
NOUGUES MAXIMO FChief Financial OfficerSep 02Sale7.511551,16467,754Sep 03 07:40 PM
HUNT DOUGLAS MSee RemarksSep 02Sale7.524223,17466,101Sep 07 03:36 PM
AUERBACH ALAN HPRESIDENT AND CEOSep 02Sale7.601,76413,4034,417,790Sep 03 09:27 PM
NOUGUES MAXIMO FChief Financial OfficerAug 02Sale7.541541,16167,909Aug 03 05:52 PM
HUNT DOUGLAS MSee RemarksAug 02Sale7.534203,16166,523Aug 03 05:49 PM
AUERBACH ALAN HPRESIDENT AND CEOAug 02Sale7.531,76413,2864,419,554Aug 03 05:45 PM
AUERBACH ALAN HPRESIDENT AND CEOJul 02Sale8.845,33247,1214,421,318Jul 06 07:42 PM
NOUGUES MAXIMO FChief Financial OfficerJul 02Sale9.261551,43568,063Jul 06 05:43 PM
HUNT DOUGLAS MSee RemarksJul 02Sale9.151,0169,29866,943Jul 06 05:40 PM
Senderowicz AdrianDirectorJun 11Sale11.1740,993457,7570Jun 15 06:14 PM
MOYES JAY MDirectorJun 10Sale11.3625,248286,8606,322Jun 11 05:36 PM
Miller Ann CalbyDirectorJun 10Sale11.4312,874147,15612,874Jun 11 04:59 PM
WILSON TROY EDWARDDirectorJun 10Sale11.3625,748292,433350Jun 11 07:30 PM
HUNT DOUGLAS MSee RemarksJun 02Sale10.774164,48167,959Jun 04 04:53 PM
AUERBACH ALAN HPRESIDENT AND CEOJun 02Sale10.741,75718,8774,426,650Jun 04 04:49 PM